TABLE 2

Baseline characteristics and changes after 1 year of treatment in women who did develop diabetes and women who did not during the PIPOD study

Variable*No diabetesDiabetesP value
Baseline
    n7511
    Age (years)39.2 ± 6.541.2 ± 7.50.36
    BMI (kg/m2)30.5 ± 4.931.0 ± 5.40.75
    Waist-to-hip circumference ratio0.86 ± 0.070.86 ± 0.060.90
    OGTT glucose area (mg · dl−1 · min−1 · 10−3)18.0 ± 2.720.4 ± 2.50.01
    OGTT insulin area (μU · ml−1 · min−1)11,579 ± 6,9397,595 ± 2,5510.08
    IVGTT insulin area (μU · ml−1 · min−1)9,954 ± 6,0517,660 ± 2,2490.37
    Si (min · μU−1 · ml−1 · 10−4)2.32 ± 1.712.41 ± 1.310.60
    AIRg (μU · ml−1 · min−1)432 ± 296251 ± 2200.05
    DI866 ± 571627 ± 6460.15
1-year changePP
    n6611
    Weight (kg)2.1 ± 4.20.00014.8 ± 3.90.0020.05
    OGTT glucose area (mg · dl−1 · min−1 · 10−3)−1.7 to 3.00.0001−1.2 ± 2.50.150.57
    OGTT insulin area (μU · ml−1 · min−1)−3,077 to 6,2110.0002243 ± 2,9700.790.01
    IVGTT insulin area (μU · ml−1 · min−1)−3,173 to 4,4470.00011,493 ± 5,2140.360.01
    Si (min · μU−1 · ml−1 · 10−4)1.33 ± 2.620.00030.77 ± 2.730.370.52
    AIRg (μU · ml−1 · min−1)23.0 ± 3850.6632.9 ± 4470.810.93
    DI511 ± 1,0330.000318 ± 1,0570.960.15
  • Data are means ± SD from women who had baseline tests and returned for at least one follow-up visit. One-year change data are from the subset of 77 women who had both an OGTT and IVGTT after 1 year of pioglitazone treatment and at least one subsequent follow-up visit.

  • *

    * Definitions of variables and units appear in Table 1.

  • By two-group t test.

  • By paired t test within each group.